Cognition Therapeutics Receives $6.6M in NIA Grants for Two

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
435
Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the receipt of two multi-year grants from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) totaling $6.6 million. These awards will fund two clinical studies of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, which are primarily designed to probe Elayta’s unique synaptoprotective mechanism of action.

Elayta has been shown in prior clinical studies to reduce the concentrations of synaptic damage proteins in the cerebrospinal fluid (CSF) of individuals with Alzheimer's disease. These results are consistent with a positive effect on synapses, suggesting that Elayta may be able to stop the loss of synapses caused by toxic beta amyloid oligomers (AβOs) and facilitate the regeneration of synapses, thus restoring memory function.

The SNAP study (COG0104) is a target engagement study that will measure the displacement of AβOs and their clearance into the CSF after a single dose of Elayta and will be undertaken at the University of Pennsylvania. The SPARC study (COG0105) is a synaptic protection study that will compare changes in synapse density following administration of Elayta or placebo for 24 weeks and will be undertaken at the Yale Alzheimer's Disease Research Unit. Both studies are expected to commence patient dosing in mid-2018.

“We are working with three esteemed investigators on these studies: Yvette I. Sheline, M.D. at the University of Pennsylvania for SNAP, and Christopher H. van Dyck, M.D. at the Yale Alzheimer's Disease Research Unit and Richard E. Carson, Ph.D. at the Yale PET Center for SPARC,” stated Cognition Therapeutics co-founder and CSO Susan Catalano, Ph.D. , who is principal investigator on both NIA grant awards. “Drs. Sheline, van Dyck and Carson are leaders in their fields and pioneers in neurocognitive disorder research. Their insights into Elayta’s mechanism of action have been invaluable, and we look forward to working with these experts and their colleagues to advance our understanding of Elayta and the underlying mechanisms of Alzheimer’s disease.”

Cognition President and CEO Kenneth I. Moch , concluded, “These NIA grant awards are important validation of and support for our novel scientific and clinical approach to treating Alzheimer’s disease. The Institute has been a long-time supporter of Cognition’s research efforts, without which we may not have achieved the research and development milestones that we have reached to date.”

The SNAP Study (COG0104) The SNAP (AβO Displacement from S ynapses on N eurons in A lzheimer’s P atients) study will randomize up to 18 patients with Aβ‑positive mild-to-moderate Alzheimer’s disease to receive a single dose of either Elayta or placebo. Plasma and CSF of study participants will be sampled hourly for 24 hours via indwelling catheters. At the end of the study period, plasma and CSF concentrations of AβOs and Elayta will be assessed to determine if Elayta’s engagement with the sigma-2 receptor complex is correlated with an increased off-rate of AβOs from their binding site on neurons. Physical and cognitive changes will also be assessed at baseline and after the 24-hour study period. This study will enroll patients at the University of Pennsylvania under the direction of Yvette I. Sheline. The SNAP study is being supported by the NIA under award number RF1AG057780. More information about SNAP may be found at www.clinicaltrials.gov under trial identifier NCT03522129.

The SPARC Study (COG0105) The SPARC ( S ynaptic P rotection for A lzheimer’s R ecovery of C ognition) study will compare changes in synaptic density in 21 Aβ-positive Alzheimer’s disease patients who will be randomized to receive treatment with one of two doses of Elayta or placebo once daily for 24 weeks. Synaptic density will be determined at baseline, 12 weeks and 24 weeks using positron emission tomography (PET) imaging with a tracer that is selective for synaptic vesicle glycoprotein 2A (SV2A), a membrane protein expressed in the majority of synapses. SPARC is world’s first study to measure longitudinal changes in synapse number using this imaging method in Alzheimer’s disease patients. Study participants will be enrolled at the Yale Alzheimer's Disease Research Unit under the direction of Christopher van Dyck and scans will be performed at the Yale PET Center under the direction of Richard E. Carson. The SPARC study is being supported by the NIA under award number RF1AG057553. More information about SPARC may be found at www.clinicaltrials.gov under trial identifier NCT03493282

About Elayta (CT1812) Cognition’s lead product candidate, Elayta (CT1812), is a highly brain penetrant small molecule with a unique disease-modifying synaptoprotective mechanism of action. This orally dosed drug candidate protects synapses by selectively displacing toxic AβOs from their synaptic receptors, thus stopping downstream damage. Elayta has been shown in preclinical models of Alzheimer’s disease to restore synapse numbers and improve memory function. Consistent with these findings, Cognition’s Phase 1b/2a clinical trial demonstrated that Elayta significantly reduces concentrations of synapse damage proteins in the cerebrospinal fluid of Alzheimer’s patients. Elayta is currently in Phase 2 clinical testing for mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the U.S. FDA.

About Cognition Therapeutics, Inc. Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, Elayta, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. Elayta and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at  http://www.cogrx.com .

Forward-Looking Statements This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.

Cognition Therapeutics, Inc. info@cogrx.com Aline Sherwood Scienta Communications asherwood@scientapr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 121

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 123

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 135

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading

Top 5 Most Recently Viewed Articles

Aardvark Therapeutics Advances Obesity Treatment Research

Updated Category News Views 140

Aardvark Therapeutics Unveils New Data on Obesity Treatments Aardvark Therapeutics, Inc. (AARD) recently showcased significant insights from its metabolic obesity pipeline at the latest conference dedicated to obesity, titled ObesityWeek 2025. This presentation highlighted the promising preclinical results of their innovative drug, ARD-201, which aims to enhance glucose...

Continue Reading
ITC Holdings Corp. Welcomes Carlo Capra as New VP of Engineering

Updated Category News Views 189

ITC Holdings Corp. Names Carlo Capra as Vice President of Engineering ITC Holdings Corp. has recently announced an important leadership change with the appointment of Carlo Capra as the company's new Vice President of Engineering, effective February 26, 2026. This move follows the retirement of Joe Bennett, who has played a vital role in ITC's development during his...

Continue Reading
Safeguarding Your Rights as a WEBTOON Entertainment Shareholder

Updated Category News Views 246

Understanding Your Rights as a WEBTOON Entertainment Shareholder Shareholders are urged to take action promptly, as the time to enforce your rights may be limited. Halper Sadeh LLC, an advocacy law firm focused on shareholder rights, is exploring claims regarding potential breaches of fiduciary duties by some officers and directors of WEBTOON Entertainment Inc. (NASDAQ:...

Continue Reading
TransDigm Group Delivers Strong First Quarter Performance

Updated Category News Views 124

TransDigm Group Reports First Quarter Results for Fiscal 2025 TransDigm Group Incorporated (NYSE: TDG), recognized as a leading designer, producer, and supplier of highly engineered aircraft components, recently announced their financial outcomes for the first quarter of fiscal 2025. First Quarter Financial Highlights In this first quarter, TransDigm Group achieved...

Continue Reading
Understanding Market Movements and TEM Stock Trends

Updated Category News Views 153

Market Activity Around Tempus AI In recent trading sessions, significant bearish sentiment has emerged around Tempus AI (TEM). This shift appears to be fueled by large investors taking notable positions that raise eyebrows among retail traders seeking insights on potential market movements. The Current Trading Landscape Today, we observed unusual activity in the options...

Continue Reading